Combined FDOPA and 3OMFD PET studies in Parkinson's disease

Journal of Nuclear Medicine

Volumn 37, Issue 2, 1996, Pages 209-216

  Dhawan, Vijay ^a   Ishikawa, Tatsuya ^b   Patlak, Clifford ^b   Chaly, Thomas ^b   Robeson, William ^b   Belakhlef, Abdelfatihe ^b   Margouleff, Claude ^b   Mandel, Francine ^b   Eidelberg, David ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

3OMFD; compartmental modeling; F DOPA; nigrostriatal dopaminergic function; Parkinson's disease; PET

Indexed keywords

6 FLUORO 3 O METHYLDOPA; 6 FLUORODOPA F 18; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORPUS STRIATUM; DISCRIMINANT ANALYSIS; DRUG DISTRIBUTION; FEMALE; FRONTAL CORTEX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; BLOOD-BRAIN BARRIER; BRAIN; CASE-CONTROL STUDIES; CORPUS STRIATUM; DECARBOXYLATION; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PARKINSON DISEASE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029937692     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 18F]fluoro-L-DOPA in human PET studies. J Cereb Blood Flow Metab 1991;11:898-913
2. 18F]fluoro-Dopa and PET: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993;13:57-69.
3. Wahl LM, Garnett ES, Chirakal R, et al. Quantification of dopamine metabolism in man: what is the most justifiable approach? J Cereb Blood Flow Metab 1993;13(suppl 1):S722
4. Gjedde A, Reith J, Dyve S, Léger G, Guttman M, Diksic M, Evans A, Kuwabara H DOPA decarboxylase activity of the living human brain. Proc Natl Acad Sci 1991;88 2721-25.
5. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
6. Hoehn MM, Yahr MD. Parkinsonism onset, progression, and mortality. Neurology 1967;17:21-25.
7. Fahn S, Elton RL, and the UPDRS Development Committee Unified Parkinson disease rating scale. In Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. vol. 2. Floral Park, New Jersey: Macmillan; 1987:293-304.
8. Robeson W, Dhawan V, Takikawa S, et al SuperPETT 3000 time-of-flight tomograph: optimization of factors affecting quantification. IEEE Trans Nucl Sci 1993;40:135-142.
9. Hariz MI, Erikson AT. Reproducibuity of repeated mounting of a noninvasive CT/MRI stereoadapter Appl Neurophysiol 1986;49:336-347.
10. 18F]fluoro-L-dopa for human studies with PET Appl Radiol Isot 1990;41:275-281.
11. 18F]fluoro-DOPA metabolism in monkeys and human, biochemical parameters for the formation of tracer kinetic models with PET. J Cereb Blood Flow Metab 1991;11:890-897.
12. 82Rb/PET studies of blood-brain barrier permeability. Phys Med Biol 1988;33:61-74.
13. 18F-DOPA uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993;13:881-888.
14. 18F]fluorodopa using a regioselective fluorodemercuration reaction. J Appl Radiat Isot 1993,45:25-30
15. Spetsieris P, Dhawan V, Takikawa S, Margouleff D, Eidelberg D A versatile graphics-image processing package for imaging cerebral function. IEEE Computer Graphics and Applications 1993;13:15-26.
16. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain New York: Thieme Medical Publishers, Inc , 1988
17. 18F]fluoro-L-DOPA in the rhesus monkey brain. J Cereb Blood Flow Metab 1991;11:726-734.
18. 18F]6-Fluoro-3-O methyl-L-dopa in the human brain. J Cereb Blood Flow Metab 1993,14 664-670.
19. 18F]fluoro-L-3,4-Dihydroxyphenylalanine in the primate. J Neurochem 1987;29: 1077-82.
20. 18F]fluoro-L-Dopa in rat J Cereb Blood Flow Metab 1990;10: 707-719.
21. Akaike A. Posterior probabilities for choosing a regression model. Ann Inst Math Sci 1978;30:9-14.
22. Patlak CS, Dhawan V, Takikawa S, et al Estimation of striatal uptake rate constant of FDOPA using PET methodological issues Ann Nucl Med 1993,7(suppl) S46-S47
23. 18F]fluoro-L-Dopa metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 1993,13:57-69.
24. Anderson TW. An introduction to multivariate statistical analysis New York. John Wiley & Sons; 1984.
25. Takikawa S, Dhawan V, Chaly T, et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism, comparative studies and clinical correlations J Nucl Med 1994;35:955-963.
26. 18F]fluoro-L-Dopa in human blood. J Nucl Med 1988;29:363-369.
27. 18F]fluorodopa positron emission tomographic studies. Mov Disorders 1990;5:203-213.
28. 11C]aminocyclohexanecarboxylate for the measurement of amino acid uptake and distribution volume in human brain. J Cereb Blood Flow Metab 1990;10.727-739
29. 18F]fluoro-L-Dihydroxyphenylalanine metabolism in the rat J Neurochem 1994;63:1675-1682
30. Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. J Nucl Med 1996,37 216-222
31. Carson RE, Doudet DJ, McLellan, et al Combined modeling analysis of 6-[F-18]fluoro-L-dopa (FDOPA) and 3-O-methyl-6-[F-18]fluoro-1-dopa (OMFD) in non-human primates. J Nucl Med 1992;33:945.
32. 18F]fluoro-L-dopa (FDOPA/PET) with an inhibitor of catechol-O-methyltransferase effect of the plasma 3-O-methyldopa fraction on data analysis [Abstract]. J Nucl Med 1995;36(suppl) 186P.
33. 18F]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurol 1992;42:199-203.
34. 18F]Fluoro-L-dopa (FD) uptake and arterial plasma tracer metabolite alterations as a result of catechol-O-methyl transferase (COMT) and L-aromatic-amino-acid-decarboxylase (AAAD). Neurology 1993 43 A196.
35. Mannisto PT, Tuomainen P, Tuominen RK Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat Br J Pharmacol 1992,105:569-574.